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Abstract
Background: Ischemia/reperfusion injury of lower extremities and associated lung damage may result from thrombotic
occlusion, embolism, trauma, or surgical intervention with prolonged ischemia and subsequent restoration of blood flow.
This clinical entity is characterized by high morbidity and mortality. Deprivation of blood supply leads to molecular and
structural changes in the affected tissue. Upon reperfusion inflammatory cascades are activated causing tissue injury. We
therefore tested preoperative treatment for prevention of reperfusion injury by using C1 esterase inhibitor (C1 INH).
Methods and Findings:Wistar rats systemically pretreated with C1 INH (n = 6), APT070 (a membrane-targeted myristoylated
peptidyl construct derived from human complement receptor 1, n = 4), vehicle (n = 7), or NaCl (n = 8) were subjected to 3h
hind limb ischemia and 24h reperfusion. The femoral artery was clamped and a tourniquet placed under maintenance of a
venous return. C1 INH treated rats showed significantly less edema in muscle (P,0.001) and lung and improved muscle
viability (P,0.001) compared to controls and APT070. C1 INH prevented up-regulation of bradykinin receptor b1 (P,0.05)
and VE-cadherin (P,0.01), reduced apoptosis (P,0.001) and fibrin deposition (P,0.01) and decreased plasma levels of pro-
inflammatory cytokines, whereas deposition of complement components was not significantly reduced in the reperfused
muscle.
Conclusions: C1 INH reduced edema formation locally in reperfused muscle as well as in lung, and improved muscle
viability. C1 INH did not primarily act via inhibition of the complement system, but via the kinin and coagulation cascade.
APT070 did not show beneficial effects in this model, despite potent inhibition of complement activation. Taken together,
C1 INH might be a promising therapy to reduce peripheral ischemia/reperfusion injury and distant lung damage in complex
and prolonged surgical interventions requiring tourniquet application.
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Introduction
Lower extremity ischemia/reperfusion injury (IRI), which may
result from thrombotic occlusion, embolism, trauma or surgical
intervention through tourniquet application and subsequent
restoration of blood flow, is of essential clinical importance. The
deprivation of blood and oxygen, termed as ischemia, leads to
time-dependent molecular and structural changes of the affected
tissue. Complex inflammatory cascades are subsequently activated
when blood flow is restored, leading to ischemia/reperfusion
injury (IRI). The hypoxic state of ischemia leads to expression of
non-muscle myosin heavy chain type II or annexin IV on the cell
surface, which function as neo-epitopes for natural antibodies
[1],[2]. This immune complex formation already occurs prior to
tourniquet release and paves the way for activation of the
complement system. Natural antibodies can activate complement
via C1q and the classical pathway or via the lectin pathway by
binding of mannose-binding lectin (MBL) to carbohydrate
structures, particularly on IgM, [3],[4] generating potent ana-
phylatoxins and ultimately resulting in the formation of a pore and
lysis of the cell. The roles of natural antibodies and the
complement system in IRI are well established, but the coagula-
tion- and the kinin systems have been shown to be of equal
importance [5]. The coagulation system plays a pivotal role in IRI
in the intestine, brain, lung and heart [6],[7], [8], [9]. The fact that
the complement system may be activated by thrombin, a protease
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of the coagulation system, highlights the complexity of the
inflammatory response in IRI [10]. In a homeostatic situation,
the inner lining of blood vessels, the endothelium, maintains an
anti-coagulatory and anti-inflammatory environment [11]. This is,
amongst others, upheld by the protective layer of the glycocalyx, a
negatively charged, tight meshwork of proteoglycans, including
heparan sulfate and other glycosaminoglycans and associated
plasma proteins. However, during ischemia the glycocalyx may be
partially lost [12], [13]. This shedding renders the anti-inflamma-
tory and anti-coagulatory state a pro-inflammatory and pro-
coagulatory one and facilitates interaction of leukocytes with the
endothelium [14].
The activation of this multifaceted network of cascades in IRI
manifests itself in edema formation and muscle necrosis. IRI of the
extremities is often accompanied by remote organ damage,
affecting organs like the liver, lung, kidney or intestine and may
lead to the development of multiple organ dysfunction syndrome
[15]. In particular, remote lung damage, which results from the
systemic inflammatory response, is a common issue [16]. It has
been shown that the expression of pro-inflammatory cytokines is
required for remote lung injury, resulting in increased vascular
permeability [17].
APT070, also known as Mirococept, is a highly effective
complement inhibitor. It is a modified fragment of the comple-
ment receptor 1 (CR1) and has binding sites for C3b and also C4b
[18]. APT070 consists of the first 3 consensus domains of the
human CR1 and a membrane-targeted synthetic peptide, which
mediates the binding to phospholipids on the cell surface and
therefore protects the cell against complement activation [19].
Beneficial effects of APT070 were shown in our lab in an in vivo
study of myocardial infarction by using a closed-chest pig model
[20].
C1 esterase inhibitor (C1 INH) is one of the main regulators of
the complement system, as it interacts with all three pathways and
additionally plays a pivotal role in the coagulation- and kinin
systems [21]. Patients deficient in C1 INH suffer from the
potentially life-threatening disorder hereditary angioedema (HAE),
emphasizing the importance of C1 INH in the healthy organism
[22]. HAE patients suffer from edema formation in the upper
airways and gastrointestinal tract, [23] mediated by bradykinin, a
member of the kinin system that enhances capillary permeability.
As C1 INH does not only act on the complement- but also on the
coagulation- and the kinin systems, it represents a promising
therapeutic option to treat IRI. Positive effects were already shown
in IRI of the heart, brain, liver and muscle [24], [25], [26,27]. We
therefore hypothesized, that C1 INH treatment in peripheral IRI
would reduce local edema formation as well as lung damage. The
effect of exogenous human plasma-derived C1 INH on tourniquet-
induced IRI was investigated in a rat hind limb model and the
underlying mechanisms of protection were analyzed.
Materials and Methods
Animals and housing
All experiments were conducted in accordance with the terms of
the Swiss animal protection law and were approved by the animal
experimentation committee of the cantonal veterinary service
(Canton of Bern, Switzerland) [28]. Male Wistar rats (wild type,
bred at the central animal facility, University of Bern) were kept in
groups of three in a clear 1500 cm2 Euro-standard Type IV S cage
(Tecniplast, Buguggiate, Italy) under standard housing conditions
with food and water ad libitum. Cages were individually ventilated
at 2062uC and 45–65% relative humidity with a circadian
rhythm of 12/12 h. During the light cycle animals were exposed
to an intensity of 200 lux. For the experiments, rats weighing
between 250 and 350 g were used.
Reagents
C1 esterase inhibitor (BerinertH) as well as the vehicle (10 mg/
ml glycine, 2.9 mg/ml sodium citrate, 8.5 mg/ml sodium
chloride, pH 7.0) were provided by CSL Behring (CSL Behring
GmbH, Marburg, Germany). APT070 was provided by King’s
College (London, UK) and consists of the first three short
consensus repeats of human complement receptor 1. APT070 is
modified with a membrane-targeting amphiphilic peptide based
on the naturally occurring membrane-bound myristoyl-electro-
static switch peptide [18]. APT070 was provided in a solution of
phosphate-buffered saline (PBS, pH 7.4) containing mannitol
(50 mg/ml) and arginine (17.4 mg/ml).
Experimental groups
Rats were divided into five groups. The experimental group
(n= 6, C1 INH group) received a dose of 50 IU/kg (50 IU/ml) of
human C1 INH. Control group 1 (n= 8, NaCl group) received 1
ml/kg of 0.9% sodium chloride. Control group 2 (n = 7, vehicle
group) received 1 ml/kg C1 INH vehicle prior to ischemia.
Control group 3 (n = 4, APT070 group) received 9 mg/kg (9 mg/
ml) of APT070 before induction of ischemia and control group 4
(n= 4, normal) underwent no intervention.
Anesthesia and analgesia
Anesthesia was induced with 2.5% isoflurane in oxygen in a box
and later maintained by inhalation of 1.5% isoflurane on a nose
mask. Analgesia was provided by 0.05 mg/kg of buprenorphine
(Temgesic, Reckitt Benckiser, Switzerland AG) injected subcuta-
neously 30 minutes prior to surgical intervention. The total
duration of anesthesia was approximately 6 h after which the rats
were allowed to wake up. To provide adequate analgesia for the
24 h reperfusion period buprenorphine injection was repeated
when animals were completely awake. After completion of 24 h
reperfusion, rats were anesthetized again as described above and
sacrificed by exsanguination during organ removal.
Surgical procedure
For assessment of limb perfusion the fur was completely
removed from both hind limbs with an electric shaver. The rats
were kept on a heating pad to maintain the body temperature at
37uC. Approximately 30 minutes after induction of anesthesia, the
femoral artery and vein were exposed via a groin incision and a
tourniquet (standardized weight of 450 g) was placed underneath
the femoral vessels to block collateral circulation [29]. The femoral
artery was then occluded for 3 h with two microvascular clamps
(B1-V, S&T, Neuhausen, Switzerland). Rat hind limbs were not
exsanguinated, but a comparable state was achieved by allowing
venous return during the entire period of ischemia in order to
prevent venous congestion and additional injury through micro-
circulatory impairment, which would not represent the clinical
situation. After 3 h of ischemia the limb was reperfused for 24 h
during which the rats were allowed to wake up with appropriate
analgesia. At the end of the experiments, tissue samples of both the
ischemic as well as the contralateral gastrocnemic muscles as well
as the lungs were taken for subsequent analyses.
Assessment of edema formation
For assessment of edema formation two samples of the
gastrocnemic muscle from both legs were taken and immediately
weighed to obtain the wet weight. The muscle samples were then
C1 Inhibitor Reduces Local and Distant IRI
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dried for 24 h at 80uC after which a constant dry weight was
achieved. Subsequently, the wet/dry ratio was calculated.
Analysis of muscle viability
IRI severely affects muscle viability, which may ultimately result
in muscle necrosis. In order to investigate the influence of C1 INH
on muscle viability the MTT (3-(4,5-dimethylthiazol-2-yl)22,5-
diphenyltetrazolium bromide, Sigma, St. Louis, USA) assay was
performed. MTT is a yellow-colored tetrazolium salt, which is
converted to purple colored formazan crystals by metabolically
active cells. Muscle samples from the gastrocnemic muscle were
taken, washed in PBS, blotted dry and incubated in 0.1 mg MTT/
ml PBS in a total volume of 3 ml at 37uC, rotating in the dark for
2 h. Thereafter, muscle samples were blotted dry and incubated in
100% isopropanol at 37uC, rotating in the dark overnight to elute
the formazan crystals from the tissue for measurement of the
optical density (OD). 200 ml of thus obtained supernatant was
measured in a microplate (Nunc, 96 well, maxisorp, transparent,
Roskilde, Denmark) with a microplate reader at 560 nm (Ref.
690 nm; Infinite M1000 spectrophotometer, Tecan, Ma¨nnedorf,
Switzerland). After drying the muscle samples at 80uC for
24 hours the OD per mg dry weight was calculated and compared
with values of contralateral control legs.
Histological assessment of damage
For assessment of hemorrhage, total myocyte damage as well as
infiltration of neutrophil granulocytes, tissue samples from the
gastrocnemic muscle were fixed in 4% formalin for 24–72 h.
Thereafter, all samples were embedded in paraffin, cut into 3 mm
thick sections and stained with hematoxylin and eosin.
Immunofluorescence analyses of tissue samples
Immunofluorescence staining using specific antibodies was used
to quantify the deposition of IgM (3020-08; Southern Biotech, AL,
USA) and IgG (3030-08; Southern Biotech), C1q (A0136, Dako,
Baar, Switzerland), MBL (clone 14C3 kindly provided from Prof.
G. Stahl, Boston, USA), C4b/c (LSB 4228, LifeSpan BioSciences
Inc., Seattle, WA, USA), C3b/c (A0062, Dako) and factor B
(341272, Calbiochem, Darmstadt, Germany). Furthermore, we
analyzed fibrin deposition (F0111; Dako, Baar, Switzerland),
expression of heparan sulfate (HS; 370255, Amsbio, Abingdon,
UK), bradykinin receptor b1 (ABR-011, Alomone Labs, Jerusa-
lem, Israel), bradykinin receptor b2 (ABR-012, Alomone Labs) as
well as VE-cadherin (sc-6458, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA). Tissue samples from the gastrocnemic
muscle of both legs and the lung were taken, washed in PBS,
blotted dry and embedded in OCT matrix (Tissue-Tek, Sakura
Finetek Europe B.V., Leiden, The Netherlands) on dry ice. The
samples were immediately stored at220uC until cryosections were
cut. Sections were fixed in acetone and rehydrated in Tris-buffered
saline (TBS). Primary antibodies were incubated overnight at 4uC
and secondary antibodies were incubated for 1 h at room
temperature (RT). Subsequently, slides were mounted and cover-
slipped. Pictures were taken with a fluorescent microscope (Leica
DMI 4000B, Leica Microsystems Schweiz AG, Heerbrugg,
Switzerland) and analyzed using Image J (National Institutes of
Health, Bethesda, MD, USA) and GraphPad Prism 5 software
(GraphPad Software, Inc., San Diego, CA, USA). Endothelial
expression of VE-cadherin as well as bradykinin receptor b1 and
b2 was analyzed in lung tissue. For this analysis, the inner lining of
the vessels was selected by hand, the surface area calculated and
the intensity of immunofluorescence measured. Area under the
curve values were obtained and divided by the surface area to
achieve a final value in intensity per square pixel.
Assessment of apoptosis using TUNEL
For assessment of apoptosis in muscle and lung tissue a TdT-
mediated dUTP nick end labeling (TUNEL) assay (in situ Cell
Death Detection Kit, TMR red, Roche, Mannheim, Germany)
was used. In brief, cryosections of muscle and lung tissue were
fixed in acetone for 5 minutes at RT, washed and permeabilized
with 0.1% Triton-X-100 on ice. Sections were incubated with
TUNEL reaction mixture for 1 h at 37uC in the dark. After a
washing step sections were mounted, coverslipped and analyzed
with a fluorescent microscope.
Analysis of infiltration of myeloperoxidase positive cells
in lung tissue
For quantitative analysis of infiltration of myeloperoxidase
(MPO) positive cells in lung tissue, embedded and frozen tissue
was cut into 5 mm thick sections, fixed in acetone and hydrated in
TBS. Tissue sections were stained with an antibody for MPO
(A0398, Dako) as well as DAPI (49,6-diamidino-2-phenylindole) to
stain nuclei. Primary antibody was incubated overnight at 4uC and
the secondary antibody (C2306, Sigma-Aldrich Chemie GmbH,
Buchs, Switzerland) as well as DAPI were incubated for 1 h at RT.
MPO positive cells were counted and divided by total number of
cells.
Cytokine/chemokine/growth factor analysis using
multiplex array
A multiplex immunoassay consisting of magnetic beads
conjugated with a capture antibody specific for a target protein
was used to detect an array of cytokines, chemokines, and growth
factors (Bio-Plex Pro Rat Cytokine Group I panel, Bio-Rad,
Hercules, CA, USA). The assay was performed according to the
manufacturer’s instructions. Briefly, plasma was diluted 1:3 and
incubated with antibody-coupled magnetic beads. A washing step
was followed by incubation with biotinylated detection antibody.
After streptavidin-phycoerythrin incubation cytokine/chemokine/
growth factor concentrations were measured. Recombinant
proteins were used to establish standard curves. Analyte concen-
trations were calculated using the Bio-Plex Manager Software.
Statistical analysis
Data are expressed as mean 6 standard deviation (SD).
Statistical significance was determined by one-way analysis of
variance with Dunnett’s post-test against NaCl control, using
GraphPad Prism 5 software. P values of ,0.05 were considered
statistically significant. Determination of n-numbers per group was
performed without formal power analysis, based on preliminary
experiments with C1 INH.
Results
Effect of C1 INH treatment on edema formation and
muscle viability as well as histological assessment of
muscle damage
Edema formation in tissue samples was analyzed as wet/dry
ratio. Edema was indicated by an increase in wet/dry ratio. C1
INH treatment (ratio 4.660.18, Figure 1B right) led to a
significant (P,0.001) reduction of fluid accumulation in the
gastrocnemic muscle in comparison to NaCl control (5.660.71,
Figure 1B left). When rats were treated with the complement
inhibitor APT070 (5.560.79) no attenuation of edema was found
(Figure 1A). Furthermore, C1 INH treated rats also showed a
significant (P,0.001) reduction in lung edema (4.760.11) as
compared to NaCl controls (5.160.15), whereas APT070 treat-
C1 Inhibitor Reduces Local and Distant IRI
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ment (5.060.10) did not lead to reduction of edema formation
(Figure 1C). Analysis of muscle viability using the MTT assay
showed that C1 INH treatment (viability 93615.3%) led to a
significant increase (P,0.001) of viability in comparison to NaCl
control (6369.4%). Again, this was not the case for APT070
treatment (6962.0%) (Figure 1D). Histologically, hemorrhage,
edema formation and myocyte destruction were apparent in NaCl-
, vehicle- and APT070 treated rats, whereas C1 INH treated rats
showed only minimal tissue damage (Figure 1E–H).
Deposition of IgM and IgG in reperfused muscle as well
as in lung tissue
Immunofluorescence stainings were performed to investigate the
impact of C1 INH treatment on antibody deposition in muscle and
lung tissue. As compared to normal rats no IgG deposits (Figure 2A)
or IgM deposits (Figure 2G) were found in contralateral legs. In the
reperfused legs high antibody deposition was found for NaCl and
vehicle control groups, whereas C1 INH (P,0.01) as well as
APT070 (P,0.001) treatment significantly reduced antibody
deposition in comparison to NaCl. Representative immunofluores-
cence images showed an intense staining for IgG (Figure 2B) and
IgM (Figure 2H) in reperfused muscles of NaCl treated rats. For C1
INH treated rats reduced deposition was detected (IgG, Figure 2C;
IgM, Figure 2I). In lung tissue no differences between groups could
be detected (Figure 2D–F and J–L).
Assessment of deposition of C3b/c and factor B in muscle
and lung tissue
Deposition of factor C3, a central component of the comple-
ment system, was analyzed using immunofluorescence staining for
the C3b/c. High deposition of C3b/c was found in the
contralateral as well as in the reperfused muscle tissue and the
lung of NaCl as well as vehicle treated rats. C3b/c deposition was
significantly reduced by APT070 treatment in both legs (P,0.01)
and in the lung (P,0.001), and by C1 INH in the contralateral leg
only (P,0.01), but not in the reperfused leg or the lung (Figure 3A–
F). Complement factor B, which is specific for alternative pathway
activation, was highly deposited in the reperfused and in the
contralateral leg as well as in lung of the NaCl control and vehicle
groups. C1 INH (P,0.01) as well as APT070 (P,0.001) treatment
significantly reduced deposition of factor B in the contralateral leg
but not in the lung and reperfused leg (Figure 3G–L).
Assessment of deposition of C1q, MBL and C4b/c in
muscle tissue
To assess deposition of classical- and lectin-pathway specific
complement components, stainings for C1q (classical pathway,
Figure 4A–F), MBL (lectin pathway, Figure 4G–I) and C4b/c
(classical and lectin pathways, Figure 4J–L) were performed. An
increased C1q deposition was found for NaCl controls in the
gastrocnemic muscle of both legs compared to normal rats
(Figure 4A). Enhanced C1q deposition was significantly reduced in
the reperfused leg by APT070 but not by C1 INH treatment,
whereas no significant differences between groups were detected in
the contralateral leg. No inter-group differences were found for
deposition of MBL (Figure 4G) as well as C4b/c (Figure 4J) in both
reperfused and contralateral legs.
Impact of C1 INH treatment on fibrin deposition as well
as heparan sulfate expression in muscle and lung tissue
To analyze the involvement of the coagulation system in
peripheral IRI and distant lung damage, muscle as well as lung
tissue was stained for fibrin deposition (Figure 5A–F). Fibrin
deposits were found in the reperfused muscle in the NaCl, vehicle
and APT070 treated groups and were significantly reduced by C1
INH (P,0.05) (Figure 5A–C). C1 INH also reduced fibrin
deposition in the lung tissue as compared to NaCl control
(P,0.01) (Figure 5D–F). The glycocalyx component heparan
sulfate (HS) was detected by immunofluorescence staining
(Figure 5G–L). Reduced HS expression was found in the
contralateral and reperfused muscle of NaCl controls. C1 INH-
treated rats showed significantly preserved expression of HS in
tissue of the contralateral muscle as compared to the NaCl control
group (P,0.01). However, in the reperfused muscle no differences
could be detected between the C1 INH and NaCl groups
(Figure 5G–I). APT070 treated rats showed significantly preserved
expression of HS in the reperfused muscle in comparison to NaCl
treated rats (P,0.05). No inter-group differences were found for
HS expression in lung tissue (Figure 5J–L).
Effect of C1 INH treatment on apoptosis in muscle and
lung tissue
Apoptosis was measured using the TUNEL assay. The ratio of
TUNEL-positive cells to total cell number was calculated.
Whereas in the contralateral muscle no apoptotic cells were
detected, cells in the reperfused muscle of the NaCl (0.7860.24),
vehicle (0.9660.06) and APT070 (0.7660.29) treated groups
showed a high degree of apoptosis. C1 INH (0.0860.18), but not
APT070, treatment led to a significant reduction of apoptotic cells
(P,0.001) in the reperfused muscle (Figure 6A–G). Similar results
were found for lung tissue, where C1 INH treated rats (0.2460.34)
also showed significantly less apoptosis as compared to the NaCl
(0.9360.05), vehicle (0.7960.18) and APT070 (0.9060.10)
(Figure 6H–N).
Effect of C1 INH treatment on expression of bradykinin
receptor b1 as well as b2 in lung tissue
Lung sections were stained for bradykinin receptor b1 (Figure 7
A–D) as well as b2 (Figure 7E–H). Specificity of bradykinin
receptor staining was verified by competitive inhibition with the
respective b1- or b2-peptides (data not shown). In contrast to
APT070, C1 INH inhibited up-regulation of bradykinin receptor
b1 in lung tissue as compared to control groups (P,0.05 vs. NaCl).
No inter-group differences were found for receptor bradykinin
receptor b2 expression.
Analysis of infiltration of myeloperoxidase positive cells
and expression of VE-cadherin in lung tissue
Infiltration of pro-inflammatory cells such as neutrophil
granulocytes was assessed by immunofluorescence staining for
myeloperoxidase. No significant differences between NaCl con-
trols and the other treatment groups could be observed. However,
C1 INH treated rats showed a trend for reduction of MPO-
positive cells (Figure 8A, B). Analysis of the expression of VE-
cadherin, a protein important for the endothelial barrier function,
in lung tissue showed an up-regulation in the NaCl control group
as compared to normal rats. Up-regulation of VE-cadherin was
prevented in C1 INH treated rats (P,0.01) (Figure 8C–F).
Analysis of plasma levels of cytokines, chemokines and
growth factors after 24 h reperfusion
Multiplex suspension array technology was used to quantify
levels of different cytokines, chemokines and growth factors in
EDTA-plasma taken after 24 h of reperfusion. Analysis revealed
that C1 INH treatment significantly reduced levels of Interleukins
(IL) IL-1a, IL-7, IL-17 and IL-18 as well as IFN-c, MIP-1a
C1 Inhibitor Reduces Local and Distant IRI
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(macrophage inflammatory protein, CCL3), MIP-3a (CCL20) and
TNF-a (P,0.05). EPO (erythropoietin), CXCL1, RANTES
(regulated and normal T cell expressed and secreted, CCl5),
VEGF (vascular endothelial growth factor), IL-4, IL-5, IL-10,
MCP-1 (monocyte chemotactic protein 1) and M-CSF (macro-
phage colony-stimulating factor) were not affected. Data are
expressed as means 6 SD. IL-1beta, IL-2, IL-6, IL12p70, IL-13,
G-CSF, GM-CSF were below detection level and are not listed
(Table 1).
Discussion
The present study aimed to investigate the effects of C1 INH
treatment on peripheral IRI and related remote lung damage.
Originally, the application of C1 INH was described in the
potentially life-threatening disease hereditary angioedema (HAE)
[30]. Lower extremity IRI is associated with edema formation in
the affected tissue, which is multifactorial and results amongst
others from increased vascular permeability [31]. It is also known
that limb ischemia may cause distant lung damage, including
pulmonary pathology with fibrin-rich microthrombus formation,
vascular congestion and pulmonary edema [32]. In the present
study we show that C1 INH protected from peripheral IRI by
reduction of skeletal muscle edema and maintenance of muscle cell
viability. In addition, lung edema formation was prevented by C1
INH treatment. Edema formation in muscle as well as lung tissue
required reperfusion. Rats subjected to ischemia only did not show
gastrocnemic muscle or lung edema (histologically assessed, data
not shown), suggesting that local, humoral or cellular components
within the reperfused limb were responsible for mediating distant
lung damage [15].
In order to investigate the mechanisms of edema reduction and
improvement ofmuscle viability, we analyzed the involvement of the
complement, coagulation and kinin systems since all three systems
play important roles in IRI pathophysiology [9,20,33]. First, the
effect of C1 INHon binding of natural IgG as well as IgM antibodies
was determined by immunofluorescence. Indeed, as compared to
normal control rats, no significant increase of antibody deposition
was found in contralateral muscle tissue as well as in lung. In
reperfusedmuscle we detected high deposition of IgG as well as IgM
in NaCl and vehicle treated groups, which was significantly reduced
by treatment with C1 INH and APT070. Both are inhibitors of the
complement system, but their evident direct effect on natural
antibody binding has not been described so far.
In order to assess which complement pathways were mainly
affected by C1 INH treatment, deposition of C3b/c (all pathways),
factor B (alternative pathway), MBL (lectin pathway), C1q
(classical pathway) as well as C4b/c (classical and lectin pathway)
were investigated. Previous studies which analyzed the effect of C1
INH treatment on peripheral IRI did not investigate deposition of
complement components at all or only as hemolytic C3 and C4
titers [34]. In our study, we showed that deposition of complement
components C4b/c and MBL was not increased by peripheral
IRI. However, an increased binding of C1q, C3b/c and factor B
was found in the contralateral as well as in the reperfused leg, but
was not significantly reduced by C1 INH treatment in the
reperfused leg. Also in lung tissue C1 INH showed no significant
effects on C3b/c and factor B deposition. In contrast, the specific
complement inhibitor APT070 significantly reduced deposition of
C1q and C3b/c in the reperfused and contralateral legs as well as
C3b/c in the lung, while not preventing edema formation or
increasing tissue viability. This finding was unexpected as
beneficial effects of APT070 were shown earlier for remote and
systemic injury following intestinal ischemia and reperfusion in rats
and myocardial reperfusion injury in pigs [35],[20]. That APT070
indeed prevented complement activation was also confirmed in
vitro by CH50 test as well as cell ELISA and cytotoxicity assay
with porcine cells and human serum (data not shown). Based on
the above mentioned data we conclude that the beneficial effects of
C1 INH treatment were not primarily due to inhibition of the
complement system.
Systemic circulation of activated complement components has
been shown in models of IRI and deposition of such components
on the endothelium of distant organs and tissues may therefore
play a role [36]. Another possibility would be that locally produced
bradykinin may lead to distant edema formation in the lung once
reperfusion starts. In our study, C1 INH treatment led to reduced
fibrin deposition in muscle as well as lung tissue. This finding is in
line with C1 INH being the main inhibitor of coagulation factors
XIa as well as XIIa [21]. Also in a mouse model of stroke it was
recently demonstrated that C1 INH treatment reduced intracere-
bral fibrin formation [37]. An important mechanism for degra-
dation of fibrin into soluble fibrin degradation products is the
fibrinolytic system. It was reported that the fibrinolytic pathway
can be initiated via direct plasminogen activation through tissue
plasminogen activator (tPA), kallikrein (KK) or factor XII, which
results in the generation of plasmin [38,39]. However, as C1 INH
inhibits plasminogen activators like FXII, KK as well as to a lesser
extent tPA and plasmin itself, increased fibrinolysis will probably
not be the main reason for reduced fibrin deposition [40,41].
Rather, C1 INH dependent inhibition of the activation of the
coagulation system may be responsible for the observed significant
reduction of fibrin deposits.
Furthermore, as a marker of the integrity of the glycocalyx, we
analyzed expression of HS in muscle as well as lung tissue. In
muscle, shedding of HS was detected as decreased expression in
the NaCl and the vehicle group in the reperfused as well as the
contralateral leg, but we did not detect any effect of peripheral IRI
on HS expression in the lung. All treatment groups, including
vehicle, showed intermediate HS expression patterns between
NaCl controls (low) and normal rat tissue [42]. Among these,
statistical significance for preservation of HS expression was
reached for C1 INH in the contralateral and for APT070 in the
reperfused leg.
Next to activation of the fibrinolytic system, factor XIIa initiates
the intrinsic pathway of coagulation via FXI activation and also
the kinin cascade by cleaving plasma prekallikrein, leading to the
formation of bradykinin. Active bradykinin binds to its b2 receptor
on the surface of endothelial cells, whereas des-arg-9-bradykinin
acts on b1 receptors, both causing vasodilation and increased
Figure 1. Effect of C1 INH on edema formation, muscle viability and histological assessment of muscle damage. (A) Analysis of edema
in the gastrocnemic muscle of both the contralateral- and reperfused legs. NaCl treated rats were compared with C1 INH, APT070 as well as vehicle
treated and normal rats. C1 INH treatment reduced muscle wet weight/dry ratio for C1 INH as compared to NaCl controls. (B) Representative images
of edema formation after 24 h reperfusion for treatment with NaCl (left) and C1 INH (right). (C) Edema formation in the lung. C1 INH treatment led to
a reduced lung wet/dry weight ratio as compared to NaCl controls. (D) Viability of the gastrocnemic muscle as assessed by MTT. C1 INH treatment
improved muscle viability as compared with NaCl controls. (E–H) Hematoxylin/eosin stained histological samples of reperfused gastrocnemic muscle.
Representative images are shown for NaCl (E) and vehicle (F) controls as well as C1 INH (G) and APT070 (H) treatment. One-way ANOVA followed by
Dunnett’s post hoc test for significance vs. NaCl controls was used. Error bars indicate mean 6 SD. *P#0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0072059.g001
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vascular permeability [43]. In contrast to b2 receptors, b1
receptors are not constitutively expressed but are induced by
pro-inflammatory cytokines. We found normal levels of the
constitutively expressed receptor b2 in all groups. However,
compared with normal rats, bradykinin b1 receptor expression was
increased in NaCl controls and this up-regulation was prevented
by treatment with C1 INH but not by APT070. This finding
corresponds with the reduced edema formation in lung tissue
found in C1 INH but not in APT070 treated or control rats and
with an earlier report showing that blocking of the b1 receptor, but
Figure 2. Analysis of deposition of IgM and IgG in muscle as well as in lung tissue. (A, D, G and J) Quantitative analysis of
immunofluorescence stainings. (A) Detection of IgG in muscle and (D) in lung tissue. (G) Detection of IgM in muscle and (J) in lung tissue. (B and C)
Representative immunofluorescence images of IgG deposition in muscle and (E and F) in lung tissue of either an NaCl or C1 INH treated rat. (H and I)
Representative immunofluorescence images of IgM deposition in muscle and (K and L) in lung tissue of either an NaCl or C1 INH treated rat. IgM as
well as IgG detectable in the red channel (CY3), counterstaining with DAPI (blue channel). One-way ANOVA followed by Dunnett’s post hoc test for
significance vs. NaCl controls was used. Error bars indicate mean 6 SD. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0072059.g002
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Figure 3. Deposition of C3b/c and factor B in muscle and lung tissue. (A, D, G and J) Quantification data of C3b/c and factor B deposition in
muscle and lung tissue, respectively. (B and C) Representative immunofluorescence images of C3b/c deposition in muscle tissue. (E and F)
Representative immunofluorescence images of C3b/c deposition in lung tissue. Counterstaining with DAPI (blue channel, only shown for muscle
tissue), C3b/c visible in the red channel (CY3). (H and I) Representative immunofluorescence images of factor B deposition in muscle tissue. (K and L)
Representative immunofluorescence images of factor B deposition in lung tissue. Counterstaining with DAPI (blue channel), factor B visible in the
green channel (Alexa 488). One-way ANOVA followed by Dunnett’s post hoc test for significance vs. NaCl controls was used. Error bars indicate mean
6 SD. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0072059.g003
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not b2 receptor, diminished brain edema formation in mice [33].
Similar results were also shown for lung as well as intestinal IRI by
using bradykinin receptor antagonists to prevent or attenuate IRI
[44,45]. However, reduced expression of b1 receptors could also
be attributed to a reduction of pro-inflammatory cytokine levels
Figure 4. Deposition of C1q, MBL and C4b/c in muscle tissue. (A, G and J) Quantification data of C1q, MBL and C4b/c deposition in muscle
tissue. (B–F) Representative immunofluorescence images of C1q deposition depending on treatment. (H and I) Representative immunofluorescence
images of MBL deposition in muscle tissue. Counterstaining with DAPI (blue channel), C1q or MBL visible in the red channel (CY3). (K and L)
Representative immunofluorescence images of C4b/c in muscle tissue, C4b/c visible in the green channel (Alexa 488). One-way ANOVA followed by
Dunnett’s post hoc test for significance vs. NaCl controls was used. Error bars indicate mean 6 SD. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0072059.g004
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Figure 5. Fibrin deposition as well as heparan sulfate (HS) expression in muscle and lung tissue. (A, D, G and J) Quantification data from
immunofluorescence stainings. (B and C) Representative immunofluorescence images for fibrin deposition. Counterstaining with DAPI (blue channel),
fibrin visible in the green channel (FITC). E and F, Representative immunofluorescence images for fibrin deposition in lung tissue. (H and I; K and L)
Representative immunofluorescence images of HS expression in muscle and lung, respectively. HS visible in the green channel (FITC). One-way
ANOVA followed by Dunnett’s post hoc test for significance vs. NaCl controls was used. Error bars indicate mean 6 SD. *P,0.05; **P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0072059.g005
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via C1 INH, as bradykinin receptor expression can be induced
through pro-inflammatory cytokine release.
Pulmonary damage secondary to local IRI can result from
embolism but also from circulatory distribution of inflammatory
mediators locally produced in the affected tissue [46]. There is no
evidence, that exclusively bradykinin is responsible for edema
formation in lung in the present model. It was reported that locally
produced humoral mediators can cause leukocyte accumulation in
Figure 6. Frequency of apoptotic cells in muscle and lung tissue. (A and H) Quantitative analysis of TUNEL staining in muscle and lung tissue,
respectively. (B–G) and (I–N) Representative immunofluorescence images of TUNEL staining of reperfused muscle and lung, respectively. TUNEL-
positive cells are shown in red (B, D, F, I, K, M), corresponding DAPI staining of all nuclei in blue (C, E, G, J, L, N). One-way ANOVA followed by
Dunnett’s post hoc test for significance vs. NaCl controls was used. Error bars indicate mean 6 SD. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0072059.g006
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lung tissue, which results in pulmonary damage by clogging of the
capillaries and release of lysosomal enzymes by leukocytes [15,47].
Furthermore, an important role in edema formation is attributed
to leukotriene B4 and other inflammatory mediators, like serotonin
or histamine [48,49].
Two studies reported that C1 INH, via expression of sialyl Lewisx
tetrasaccharides and binding to E- and P-selectins, prevents
Figure 7. Endothelial expression of bradykinin receptor b1 as well as b2 in lung tissue. (A and E) Quantification data from
immunofluorescence stainings. (B–D) Representative immunofluorescence images of bradykinin receptor b1 as well as (F–H) bradykinin receptor b2
staining in vessels of lung tissue. One-way ANOVA followed by Dunnett’s post hoc test for significance vs. NaCl controls was used. Error bars indicate
mean 6 SD. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0072059.g007
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adhesion and migration of leukocytes to the endothelium in vitro as
well as in vivo [50,51]. We analyzed infiltration of MPO-positive
cells in lung tissue and indeed a trend, albeit not significant, was
found for a reduction of MPO positive cells by C1 INH.
We also analyzed the expression of VE-cadherin, which is a
component of adherens junctions of endothelial cells and
contributes to their barrier function [52]. In vessels of lung tissue
we found elevated levels of VE-cadherin in NaCl, vehicle as well as
APT070 treated rats, whereas C1 INH treated rats showed VE-
cadherin expression levels similar to normal rats. Currently, not
much is known about the mechanisms by which VE-cadherin-
mediated cell-cell junctions are regulated. It could be speculated
that in the present study the increase of VE-cadherin expression
could be due to repair mechanisms, whereas C1 INH maintains
endothelial cell integrity and avoids activation of these mecha-
nisms [53]. However, a more detailed analysis of the mechanism of
Figure 8. Infiltration of myeloperoxidase positive cells in lung tissue as well as VE-cadherin expression. (A) Quantitative evaluation and
(B) representative immunofluorescence image of MPO expression in lung tissue. The blue channel shows DAPI staining, the red channel (CY3) shows
MPO positive cells. (C) Quantification data from immunofluorescence stainings of VE-cadherin. (D–F) Representative images of VE-cadherin staining.
One-way ANOVA followed by Dunnett’s post hoc test for significance vs. NaCl controls was used. Error bars indicate mean 6 SD. *P,0.05; **P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0072059.g008
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VE-cadherin regulation in IRI would be necessary to support this
hypothesis, which is beyond the scope of the present study.
In IRI apoptosis plays an important pathophysiological role and
is an event of reperfusion, as it requires energy and is associated
with cell shrinkage and phagocytosis without loss of membrane
integrity [54]. In our study, C1 INH treated rats showed
significantly less apoptosis as compared to the NaCl control
group. These data confirm earlier reports describing that C1 INH
improves the outcome of myocardial IRI via anti-apoptotic
activity independent of its serine protease inhibitory activity by
normalization of ratio of the Bcl-2/Bax expression [55]. Further-
more, it was shown that C1 INH reduced infarction size in a
mouse model of myocardial infarction via inhibition of leukocyte
transmigration into the ischemic tissue, which is also not mediated
through its protease activity [56].
The systemic inflammatory response, which is initiated in IRI is
characterized by the release of pro-inflammatory cytokines, like
TNF-a [57]. Our results demonstrated that C1 INH treatment led
to significantly reduced levels of several pro-inflammatory
cytokines. In a model of myocardial IRI it was shown that IL-
17A plays a pathogenic role by inducing cardiomyocyte apoptosis
and neutrophil infiltration [58]. We found reduced plasma levels
of IL-17A in C1 INH treated rats, which fits with the observed
reduction of apoptosis in muscle and lung tissue by C1 INH
treatment. Also MIP-1a plays an important role in mediating an
acute inflammatory response – another chemokine that was
significantly reduced in C1 INH treated rats in our study [59].
In 2004, Inderbitzin and colleagues presented a study of
transgenic mice overexpressing human C1 INH (plasma levels of
1–2 mg/ml), which were used for a lower torso IRI model. They
found that muscle as well as lung tissue was protected from
endothelial cell damage by measuring the amount of extravasation
of 125I-labelled albumin, reflecting a direct functional measurement
of endothelial integrity [53]. We showed here for the first time in
non-transgenic animals that C1 INH at a low, clinically applicable
dose of 50 IU/kg significantly reduced peripheral IRI inmuscle and,
in particular, that also lung injury was significantly reduced.
In conclusion, C1 INH is a multifaceted protein, which acts on
multiple inflammatory cascades relevant in IRI pathology. Via
inhibition of kallikrein, FXIa, FXIIa as well as the complement
system, it regulates IRI associated inflammatory and thrombotic
processes. Our data support the regulatory effect of C1 INH on
the coagulation- and the kinin system in IRI. A very potent
inhibitory effect of human C1 INH on edema formation and
apoptosis in skeletal muscle as well as in lung was observed. In
addition, the up-regulation of bradykinin receptor b1 was
prevented by C1 INH. These results may be a hint that C1
INH plays an important role in inhibition of the kinin system in
this animal model of hind limb IRI. Furthermore, C1 INH also
prevented fibrin deposition. Analysis of the effect of C1 INH on
the complement cascades revealed that C1 INH reduced
peripheral IRI not primarily by inhibition of the complement
system. This conclusion is supported by APT070 data, which
showed a significant reduction of C1q and C3b/c in the
reperfused leg, but did not reduce edema formation in muscle
and lung tissue. Furthermore, C1 INH reduced plasma levels of
IFN-c, IL-1a, IL-7, IL-17A, IL-18, MIP-1a, MIP-3a and TNF-a.
All in all, C1 INH may provide a promising therapy to reduce
peripheral IRI as well as distant lung injury in complicated and
prolonged surgical interventions requiring tourniquet application.
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